BRIEF-Acceleron outlines corporate goals and priorities for 2017
January 06, 2017 at 07:07 AM EST
* Plan to initiate new luspatercept phase 2 clinical trials in distinct patient segments in MDS and Beta-Thalassemia
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.